| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.074 | 0.02 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.077 | 0.02 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.02 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.09 | 0.02 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.078 | 0.02 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | 0.13 | 0.02 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | -0.083 | 0.02 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | selumetinib:BRD-A02303741 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.081 | 0.02 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | -0.099 | 0.02 |